Guardian Investment Management Gilead Sciences, Inc. Transaction History

Guardian Investment Management

$125 Million
Q3 2024

A detailed history of Guardian Investment Management transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Guardian Investment Management holds 5,650 shares of GILD stock, worth $523,077. This represents 0.38% of its overall portfolio holdings.

Number of Shares

5,650

Previous 5,650 -0.0%

Holding current value

$523,077

Previous $387,000 22.22%

% of portfolio

0.38%

Previous 0.27%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 23, 2024	SELL	$63.15 - $72.88 $15,787 - $18,220	-250 Reduced 4.24%	5,650 $387,000
Q4 2023 Jan 31, 2024	SELL	$73.27 - $83.09 $120,895 - $137,098	-1,650 Reduced 21.85%	5,900 $477,000
Q2 2023 Jul 14, 2023	SELL	$76.01 - $86.7 $452,259 - $515,865	-5,950 Reduced 44.07%	7,550 $581,000
Q1 2023 May 05, 2023	BUY	$77.31 - $88.08 $440,667 - $502,056	5,700 Added 73.08%	13,500 $1.12 Million
Q4 2022 Jan 12, 2023	SELL	$62.32 - $89.47 $174,496 - $250,516	-2,800 Reduced 26.42%	7,800 $0
Q3 2022 Oct 12, 2022	SELL	$59.54 - $68.01 $77,402 - $88,413	-1,300 Reduced 10.92%	10,600 $653,000
Q1 2022 Apr 22, 2022	SELL	$57.92 - $72.58 $17,376 - $21,774	-300 Reduced 2.46%	11,900 $707,000
Q3 2021 Oct 13, 2021	SELL	$67.69 - $73.03 $33,845 - $36,515	-500 Reduced 3.94%	12,200 $852,000
Q2 2021 Jul 14, 2021	SELL	$63.47 - $69.35 $50,776 - $55,479	-800 Reduced 5.93%	12,700 $875,000
Q1 2021 Apr 14, 2021	SELL	$60.0 - $68.46 $30,000 - $34,230	-500 Reduced 3.57%	13,500 $875,000
Q4 2020 Jan 19, 2021	BUY	$56.65 - $64.55 $793,100 - $903,700	14,000 New	14,000 $816,000

Others Institutions Holding GILD

# of Institutions

1,927

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Guardian Investment Management, based on Form 13F filings with the SEC.

News

Stay updated on Guardian Investment Management with notifications on news.

Account

Guardian Investment Management Gilead Sciences, Inc. Transaction History